Felty's and pseudo-Felty's syndromes

Rosenstein, Elliot D.; Kramer, Neil

doi:10.1016/0049-0172(91)90002-h

Cited by 65 publications

(43 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is unclear, however, whether patients with these disorders represent 2 distinct subsets of neutropenic RA. Indeed, the disorder of LGL leukemia with RA has been termed pseudo-Felty's syndrome (5). To examine this question, we determined the HLA-DR4 type of 22 patients with Felty's syndrome and 22 patients with LGL leukemia, 10 of whom had RA.…”

Section: Immunogenetic Similarities Between Patients With Felty's Synmentioning

confidence: 99%

Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis

Starkebaum

Loughran

Gaur

et al. 1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

Objective. Patients with chronic clonal proliferation of large granular lymphocytes (LGL leukemia) often have splenomegaly, neutropenia, and rheumatoid arthritis (RA), thereby resembling the manifestations observed in patients with Felty's syndrome. The present study sought to determine whether patients with these disorders represent 2 distinct subsets of neutropenic RA. Methods. Prospective cohort study of outpatients attending clinics in university and private hospitals and in offices of private practice physicians. Twenty‐two patients with Felty's syndrome and 22 patients with LGL leukemia, 10 of whom had RA, were studied. HLA genotyping was performed on peripheral blood mononuclear leukocyte genomic DNA. Results. Nineteen of the 22 patients with Felty's syndrome (86%) were DR4 positive. Nine of the 10 patients with LGL leukemia plus RA were also DR4 positive. In contrast, only 4 of the 12 patients with LGL leukemia without RA (33%) were DR4 positive, a frequency that was within the normal range. Conclusion. The finding of an equally high prevalence of DR4 in patients with Felty's syndrome and in those with LGL leukemia plus RA suggests that both disorders have a similar immunogenetic basis and are parts of a single disease process rather than 2 separate disorders.

show abstract

Section: Immunogenetic Similarities Between Patients With Felty's Synmentioning

confidence: 99%

Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis

Starkebaum

Loughran

Gaur

et al. 1997

Arthritis & Rheumatism

View full text Add to dashboard Cite

show abstract

“…For example, Robinson et al (247) Lithium causes leukocytosis (14,110,276,304,325). At high doses of 50 mg/kg, lithium significantly infound that lithium enhances peripheral blood neutrophil, serum CSA levels, and other symptoms in Felty's syncreases total leukocyte count and neutrophil count, reduces lymphocyte count, and increases erythrocyte count drome (284), an autoimmune condition with rheumatoid arthritis, leukopenia, and splenomegaly (248). In some and hematocrit in rats (147).…”

Section: Lithium-induced Granulocytosismentioning

confidence: 99%

Review of Lithium Effects on Brain and Blood

2009

View full text Add to dashboard Cite

Clinicians have long used lithium to treat manic depression. They have also observed that lithium causes granulocytosis and lymphopenia while it enhances immunological activities of monocytes and lymphocytes. In fact, clinicians have long used lithium to treat granulocytopenia resulting from radiation and chemotherapy, to boost immunoglobulins after vaccination, and to enhance natural killer activity. Recent studies revealed a mechanism that ties together these disparate effects of lithium. Lithium acts through multiple pathways to inhibit glycogen synthetase kinase-3β (GSK3β). This enzyme phosphorylates and inhibits nuclear factors that turn on cell growth and protection programs, including the nuclear factor of activated T cells (NFAT) and WNT/β-catenin. In animals, lithium upregulates neurotrophins, including brain-derived neurotrophic factor (BDNF), nerve growth factor, neurotrophin-3 (NT3), as well as receptors to these growth factors in brain. Lithium also stimulates proliferation of stem cells, including bone marrow and neural stem cells in the subventricular zone, striatum, and forebrain. The stimulation of endogenous neural stem cells may explain why lithium increases brain cell density and volume in patients with bipolar disorders. Lithium also increases brain concentrations of the neuronal markers n-acetyl-aspartate and myoinositol. Lithium also remarkably protects neurons against glutamate, seizures, and apoptosis due to a wide variety of neurotoxins. The effective dose range for lithium is 0.6-1.0 mM in serum and >1.5 mM may be toxic. Serum lithium levels of 1.5-2.0 mM may have mild and reversible toxic effects on kidney, liver, heart, and glands. Serum levels of >2 mM may be associated with neurological symptoms, including cerebellar dysfunction. Prolonged lithium intoxication >2 mM can cause permanent brain damage. Lithium has low mutagenic and carcinogenic risk. Lithium is still the most effective therapy for depression. It "cures" a third of the patients with manic depression, improves the lives of about a third, and is ineffective in about a third. Recent studies suggest that some anticonvulsants (i.e., valproate, carbamapazine, and lamotrigene) may be useful in patients that do not respond to lithium. Lithium has been reported to be beneficial in animal models of brain injury, stroke, Alzheimer's, Huntington's, and Parkinson's diseases, amyotrophic lateral sclerosis (ALS), spinal cord injury, and other conditions. Clinical trials assessing the effects of lithium are under way. A recent clinical trial suggests that lithium stops the progression of ALS.

show abstract

“…Полная триада не является абсолютным требова-нием, но стойкая лейкопения и нейтропения с абсолют-ным числом нейтрофилов <1,5•10 9 /л обязательны для то-го, чтобы обсуждать диагноз CФ [52]. В действительности нейтропения является наиболее распространенным и важным признаком СФ, в отличие от спленомегалии, которая не всегда возникает одновременно с нейтропени-ей [55]. Лейкопенией считают количество лейкоцитов <3•10 9 /л с абсолютным количеством нейтрофилов <2,0•10 9 /л [56], но наибольшее число инфекций наблю-далось, когда количество нейтрофилов не превышало 0,5•10 9 /л [52].…”

Section: клинико-диагностический анализ внесуставных проявленийunclassified

“…Так, из 100 больных СФ, наблюдавшихся в кли-нике Мейо в течение 5 лет, 35 не потребовалось лечение из-за отсутствия симптомов артрита [52,54,55]. СФ мо-жет быть бессимптомным, но обычно проявляется ло-кальной или системной инфекцией, чаще кожной или ле-гочной [19].…”

Section: клинико-диагностический анализ внесуставных проявленийunclassified

Extra-Articular Manifestations of Rheumatoid Arthritis

Муравьев¹

2018

rsp

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is an immune inflammatory (autoimmune) rheumatic disease of unknown etiology, which is characterized by chronic erosive arthritis and systemic damage to the viscera, and leads to early disability and reduced survival in patients. For its diagnosis, it is currently recommended to use the 2010 ACR/EULAR classification criteria for RA, which should be applied in clinical trials to identify at least one swollen joint, i.e. the presence of arthritis; therefore, the problem of extra-articular manifestations of RA is apparent to stay in the background.

show abstract

Felty's and pseudo-Felty's syndromes

Cited by 65 publications

References 88 publications

Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis

Immunogenetic similarities between patients with Felty's syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis

Review of Lithium Effects on Brain and Blood

Extra-Articular Manifestations of Rheumatoid Arthritis

Contact Info

Product

Resources

About